Application | Comment | Organism |
---|---|---|
diagnostics | GCNT3 might be an essential glycosylation-related molecule in colorectal cancer and epithelial ovarian cancer progression, with potential interest as a predictive biomarker of response to chemotherapy. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome. Clinical relevance of GCNT3 expression in epithelial ovarian cancer (EOC), role of GCNT3 as a biomarker for cancer patients, overview | Homo sapiens |
Cloned (Comment) | Organism |
---|---|
gene GCNT3, recombinant overexpression in SW620 and SW5FU cell lines, genomic analysis of GCNT3 overexpression, quantitative RT-PCR enzyme expression analysis, genomic and proteomic landscapes of GCNT3 are linked to cell cycle and response to drug pathways. GCNT3 overexpression does not significantly change cell growth in Caov3 cells, VEGFA expression is downregulated in GCNT3 Caov3 cells | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
additional information | GCNT3 downregulation by shGCNT3 7. GCNT3 overexpression reduces 5-fluorouracil resistance in colorectal cancer (CRC) cells. GCNT3 overexpression reduces proliferation, invasion and changes metabolic capacities of CRC cells. Genomic analysis of GCNT3 overexpression, overview | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | O95395 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
colon | - |
Homo sapiens | - |
colorectal cancer cell | GCNT3 gene expression is downregulated in colorectal cancer (CRC) samples in comparison to non-pathological colon tissue | Homo sapiens | - |
epithelial ovarian cancer cell | GCNT3 expression analysis in a cohort of 56 EOC patients, followed by a meta-analysis of more than one thousand patients, overview | Homo sapiens | - |
HT-29 cell | high levels of endogenous GCNT3 | Homo sapiens | - |
additional information | integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation. The non-invasive HT-29 cell line, that is isolated from a primary tumor, shows GCNT3 expression (mRNA and protein). By contrast, cells belonging to metastatic and invasive SW family, e.g. SW620 and SW5FU, do not exhibit measurable GCNT3 expression | Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
c2GnT-M | - |
Homo sapiens |
gcnt3 | - |
Homo sapiens |
More | see also EC 2.4.1.150 | Homo sapiens |
mucin-type core 2 1,6-N-acetylglucosaminyltransferase enzyme | - |
Homo sapiens |
Organism | Comment | Expression |
---|---|---|
Homo sapiens | GCNT3 downregulation by shGCNT3 7, of several shRNAs targeting GCNT3 shGCNT3s, shGCNT3 7 has the best inhibitory capacity (protein and mRNA) | down |
Homo sapiens | modulation of GCNT3 expression in the presence of 5-fluorouracil (5FU) at 0.03 mM, a robust induction of GCNT3 expression is observed in SW family of non-resistant cells with a statistically significant 3.76fold increase in SW620 metastatic cells, while no such induction is observed in SW5FU cells or in HT-29 cell line, which has the highest levels of endogenous GCNT3 | up |
General Information | Comment | Organism |
---|---|---|
malfunction | GCNT3 overexpression reduces 5-fluorouracil resistance in colorectal cancer (CRC) cells. GCNT3 overexpression reduces proliferation, invasion and changes metabolic capacities of CRC cells. The enzyme's overexpression in epithelial ovarian cancer (EOC) patients is associated with better clinical outcome and response to initial therapy | Homo sapiens |
metabolism | integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation, response to drugs and metabolism pathways. The vascular epithelial growth factor A (VEGFA) arises as an attractive partner of GCNT3 functions in cell invasion and resistance | Homo sapiens |
physiological function | the mucin-type core 2 1,6-N-acetylglucosaminyltransferase enzyme (C2GnT-M), encoded by the GCNT3 gene, is a glycosyltransferase enzyme whose expression is altered in cancer processes. GCNT3 catalyzes the formation of core 2 O-glycan, core 4 O-glycan and I branches and its pattern of expression is mainly associated with colorectal cancer (CRC) prognosis. GCNT3 transfection in certain CRC cells reduces cell proliferation, adhesion, invasion, and induced cell death, and also inhibits tumor growth in vivo. Role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance, overview. Integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation, response to drugs and metabolism pathways. GCNT3 overexpression contributes to reduce 5-fluorouracil resistance in metastatic CRC cells. GCNT3 also diminishes cell invasion and VEGFA expression in EOC cells. GCNT3 is a cancer prognostic factor. GCNT3 diminishes cell proliferation, invasion and alters metabolic properties of CRC cells. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome | Homo sapiens |